Imaging-based endpoints play a valuable role in oncology clinical trials. Quantifying the size and number of tumors visualized by imaging provides insights into drug efficacy much faster than relying on traditional clinical endpoints such as patient survival.
Use of imaging as a surrogate endpoint can therefore be a powerful means of demonstrating unmet clinical needs and ultimately accelerating approval of a new drug.
Imaging endpoint assessments are highly dependent on measurement techniques, assessment guidelines, available technology tools and image reviewer expertise. It is critical to avoid introducing bias or variability, which can jeopardize the identification of true safety and efficacy differences among treatment groups.
Date: March 16th, 2017
Time: 8:30 – 10:30
Address: Arne Jacobsens Allé 15, 2300 Copenhagen S
Room: Ground floor
Program
| 08.30-09.00 | Coffee and networking |
| 09.00-10.00 | Medical Imaging in oncology trials – incl. Q&A |
| Topics will include: | |
| – Why BICR – Blinded Independent Central Read? | |
| – What to consider when planning an oncology study with imaging? | |
| – Assessment criteria overview | |
| – Discussion | |
| 10.00-10:30 | Networking |
Speakers:
 |
 |
| Dr. Oliver Bohnsack Senior Director Medical Affairs PAREXEL |
Manuela Lesch, RT |
In cooperation with:
